Inflammation & cardiovascular disease: Exploring new options for intervention
Presentations of this session will be posted soon
EBAC ACCREDITED EDUCATIONAL PROGRAMME HELD DURING THE ESC CONGRESS 2013
Skopje – Village 5
Monday, September 2, 2013, 12:45 – 13:45 hrs
12:45 – 12:50 Introduction
John Kastelein – AMC, Amsterdam, the Netherlands
John Deanfield – UCL, London, United Kingdom
12:50 – 13:05 Inflammation biology in atherosclerosis
Peter Libby – Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
13:05 – 13:20 Biomarkers of inflammation and atherosclerotic risk
Wolfgang Koenig – University of Ulm, Ulm, Germany
13:20 – 13:35 Targeting inflammation in prevention of atherosclerotic events
Paul Ridker – Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
13:35 – 13:45 Q&A & summary
John Kastelein, John Deanfield
Organized and supervized by University College London, Course director; Prof John Deanfield
1 hour of external CME credit(s). Each participant should claim only those hours of credit that have
actually been spent in the educational activity.
EBAC works according to the quality standards the European Accreditation for Continuing Medical
Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).
To secure a seat at the symposium please pre-register via this link
Download PACE-ESC Inflammation and CV disease symposium invite.pdf
“In compliance with EBAC/ EACCME guidelines, all speakers/Chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.
The Organising Committee/ Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.”
EBAC ACCREDITED EDUCATIONAL PROGRAMME HELD DURING THE ESC CONGRESS 2013
Skopje – Village 5
Monday, September 2, 2013, 12:45 – 13:45 hrs
Educational objectives
- Review the current evidence supporting the inflammatory hypotheses of atherothrombosis
- Review the epidemiology of hsCRP in risk stratification in CV disease
- Discuss the rationale for lowering vascular events by inhibition of inflammation
- Discuss the mechanism of blocking the pro-inflammatory cytokine interleukin-1β (IL-1β) with a monoclonal antihuman antibody
- Discuss the potential of current and future strategies targeting inflammation in cardiovascular disease
- Outline current ongoing clinical development programs aimed to address the inflammation hypothesis in cardiovascular disease
Agenda
12:45 – 12:50 Introduction
John Kastelein – AMC, Amsterdam, the Netherlands
John Deanfield – UCL, London, United Kingdom
12:50 – 13:05 Inflammation biology in atherosclerosis
Peter Libby – Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
13:05 – 13:20 Biomarkers of inflammation and atherosclerotic risk
Wolfgang Koenig – University of Ulm, Ulm, Germany
13:20 – 13:35 Targeting inflammation in prevention of atherosclerotic events
Paul Ridker – Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
13:35 – 13:45 Q&A & summary
John Kastelein, John Deanfield
Organized and supervized by University College London, Course director; Prof John Deanfield
CME Accreditation
This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for1 hour of external CME credit(s). Each participant should claim only those hours of credit that have
actually been spent in the educational activity.
EBAC works according to the quality standards the European Accreditation for Continuing Medical
Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).
Registration
Acces to this symposium is only for delegates registered for the ESC 2013 congressTo secure a seat at the symposium please pre-register via this link
Download PACE-ESC Inflammation and CV disease symposium invite.pdf
Funding
Supported by an unrestricted educational grant from Novartis.“In compliance with EBAC/ EACCME guidelines, all speakers/Chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.
The Organising Committee/ Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.”
Share this page with your colleagues and friends: